US Stock MarketDetailed Quotes
AIMD Ainos
- 0.5731
- -0.0829-12.64%
Close Jan 8 16:00 ET
- 0.5690
- -0.0041-0.72%
Post 19:23 ET
8.07MMarket Cap-0.21P/E (TTM)
0.6665High0.5200Low293.75KVolume0.6400Open0.6560Pre Close164.54KTurnover2.95%Turnover RatioLossP/E (Static)14.09MShares3.100052wk High0.45P/B5.71MFloat Cap0.400052wk Low--Dividend TTM9.96MShs Float356.2500Historical High--Div YieldTTM22.33%Amplitude0.4000Historical Low0.5600Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Ainos Stock Forum
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
Ainos (NASDAQ: AIMD) has signed a strategic Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku, a subsidiary of Mitsubishi Tanabe Pharma , to advance the manufacturing and Taiwan market promotion of VELDONA®, their Sjögren's syndrome treatment drug. The partnership leverages Taiwan Tanabe Seiyaku's pharmaceutical dev...
SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has receive...
Ainos Files Complaints With Nasdaq MarketWatch And The SEC Of Concerns Over Large-Volume Sell Orders, Says It 'Suspects That These Trading Activities May Involve Regulatory Violations'
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Ainos, Inc. (NASDAQ:AIMD) has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial on VELDONA®, a low-dose oral interferon formulation for treating oral warts in HIV-positive patients. The trial, involving 40 participants, will evaluate VELDONA®'...
No comment yet